Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by Two Sigma Investments LP

Two Sigma Investments LP boosted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 43.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 127,320 shares of the company's stock after buying an additional 38,500 shares during the period. Two Sigma Investments LP owned 0.18% of Akero Therapeutics worth $3,542,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC raised its holdings in shares of Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after purchasing an additional 1,582 shares during the period. Quarry LP purchased a new position in shares of Akero Therapeutics in the 4th quarter worth about $83,000. Summit Investment Advisors Inc. raised its holdings in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock valued at $197,000 after buying an additional 450 shares during the period. Hsbc Holdings PLC raised its holdings in shares of Akero Therapeutics by 8.5% during the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock valued at $220,000 after buying an additional 621 shares during the period. Finally, AlphaQuest LLC raised its holdings in shares of Akero Therapeutics by 32,588.0% during the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after buying an additional 8,147 shares during the period.

Insider Buying and Selling

In other news, CEO Andrew Cheng sold 30,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $41.77, for a total value of $1,253,100.00. Following the completion of the transaction, the chief executive officer now owns 656,062 shares of the company's stock, valued at approximately $27,403,709.74. This represents a 4.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Patrick Lamy sold 4,000 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $50.00, for a total value of $200,000.00. Following the completion of the transaction, the vice president now directly owns 33,492 shares of the company's stock, valued at approximately $1,674,600. The trade was a 10.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 172,208 shares of company stock worth $7,022,204 in the last three months. 7.94% of the stock is owned by insiders.

Analyst Ratings Changes

AKRO has been the topic of several analyst reports. Citigroup dropped their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Bank of America raised their target price on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a report on Tuesday, May 27th. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, HC Wainwright lifted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $82.50.

Akero Therapeutics Stock Performance

AKRO traded up $0.88 during trading on Tuesday, reaching $51.61. 2,140,559 shares of the company were exchanged, compared to its average volume of 990,644. The stock has a market cap of $4.11 billion, a P/E ratio of -13.76 and a beta of -0.12. The firm has a 50 day moving average of $41.52 and a 200 day moving average of $39.09. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 52 week low of $17.86 and a 52 week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. On average, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.